Mitochondrial DNA variants function as potential genetic risk factors for Parkinson disease
Objective: To understand whether mtDNA variants contribute to the susceptibility to sporadic PD. Background: It is well-recognized that mitochondrial (mt) dysfunction is involved in the…Characterization of Noncoding Variant(s) Driving Genome-Wide Association of the PARK10 Locus in Autopsy-Proven Parkinson Disease and Controls.
Objective: Confirm the PARK10 locus as a major GWAS locus in autopsy-confirmed (AC) PD and AC controls and identify potential noncoding variants driving the association. …Improving Diagnosis and Treatment of Anxiety in Parkinson’s Disease: IDATA-PD Study
Objective: We investigated PD-specific features of anxiety for clear conceptualisation, and assessed targeted psychotherapy for anxiety in Parkinson’s disease (PD). Background: Anxiety is poorly diagnosed in PD…Tongue strength in Parkinson’s disease.
Objective: To investigate tongue strength in patients with Parkinson’s disease and the relation with speech and swallowing. Background: Motor disorders in Parkinson’s disease (PD) are…High intensity interval training improves psychomotor function in individuals with Parkinson’s disease
Objective: The study aimed to examine the effects of high intensity interval training (HIIT) on neurological, psychological and biomechanical aspects of psychomotor behaviors in Parkinson’s…Developing a guide to facilitate involving people with Parkinson’s and their carers in service improvement
Objective: To develop an easy-to-use guide for service development project leads and patients/carers to facilitate the involvement of the latter in the development and implementation…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Four year outcomes of a prospective, multi-center trial evaluating Deep Brain Stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease
Objective: To evaluate the four year, long-term follow up results of patients in the VANTAGE clinical study that employed multiple independent current control (MICC) Deep Brain…Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study
Objective: To determine the longitudinal change in the Movement Disorder Society –Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) in Parkinson’s disease (PD) participants who were untreated…A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily to slow progression of disability in early PD. Background: Isradipine, a dihydropyridine calcium channel antagonist,…
- « Previous Page
- 1
- …
- 274
- 275
- 276
- 277
- 278
- …
- 388
- Next Page »